Press Releases

Press Releases

SAN DIEGO , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in February and March: SVB Leerink 10th Annual Global Healthcare Conference Date: Wednesday, February
Feb 22, 2021
SAN DIEGO , Feb. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 6,550,000 shares of its common stock at a price to the public of $26.75 per share. All of the shares are being sold by Travere.
Feb 11, 2021
SAN DIEGO , Feb. 10, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $150,000,000 of its common stock. All of the shares are being offered by Travere.
Feb 10, 2021
SAN DIEGO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company’s ongoing pivotal Phase 3 DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS) achieved its pre-specified interim FSGS partial remission of proteinuria endpoint (FPRE) after 36 weeks of treatment.
Feb 02, 2021